Alan Bonder

Effective primary biliary cholangitis (PBC) management is vital due to its progression to cirrhosis and its impact on survival. Ursodeoxycholic acid (UDCA) is the main therapy, but predicting treatment response is challenging…

Introduction: Cholangiocarcinoma (CCA) is the second most common primary neoplasm of the liver after hepatocellular carcinoma (HCC) and is associated with a high rate of mortality…

INTRODUCTION: Obeticholic acid (OCA), a potent farnesoid X receptor agonist, is indicated as a second-line treatment for patients (pts) with primary biliary cholangitis (PBC) who have an inadequate response or intolerance to ursodeoxycholic acid…

INTRODUCTION: Transient elastography (TE) is a noninvasive alternative to biopsy for assessment of liver stiffness and indirectly fibrosis, which can be predictive of adverse outcomes in patients with primary biliary cholangitis (PBC)…

METABOLIC OUTCOMES AND KEY EFFICACY DATA FROM A PHASE 2 TRIAL EVALUATING COMBINATION OBETICHOLIC ACID AND BEZAFIBRATE IN PATIENTS WITH PRIMARY BILIARY CHOLANGITIS